BDNF and Tau as biomarkers of severity in multiple sclerosis.

Aim: Determine if serum levels of tau and BDNF can be used as severity biomarkers in multiple sclerosis (MS).

Patients & Methods: Subjects with MS, older than 18 and younger than 55 years old were included; 74 patients with a diagnosis of relapsing-remitting MS, 11 with secondary-progressive MS, and 88 controls were included. Total tau and BDNF were measured by Western blot.